Skip to main content
SpringerLink
Log in

Effects of cyclooxygenase-2 (COX-2) inhibitors in colorectal cancer

  • Chapter
Cancer and Inflammation

Part of the book series: Progress in Inflammation Research ((PIR))

  • 133 Accesses

Abstract

Colorectal cancer is one of the leading causes of cancer-related deaths in the western world [1, 2]. In the United States, colorectal cancer is the second most common form of malignant tumor [3]. Therefore, prevention of this disease has been more and more focused recently [4]. The use of colorectal cancer-screening programs has resulted in a decrease in the incidence and the mortality rates of colorectal cancer [5,6]. However, the acceptance of screening tests is low [7-9]. Thus, current screening and treatment strategies for colorectal cancer are not sufficiently effective [10]. Recently, some studies reported that cyclooxygenase (COX) inhibitors are able to reduce the incidence of colorectal adenoma and colorectal cancer and that the mortality rate from colorectal cancer may be improved by up to 65% [11-14]. Furthermore, the inhibition of COX-2 activity in patients with familial adenomatous polyposis (FAP) syndrome seems to be related to a reduced formation of colorectal polyps [15]. The following chapter discusses the mechanism of action and the role of COX-2 inhibitors in prevention of colorectal cancer, based on a broad literature search.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ladabaum U, Chopra CL, Huang G, Schelman JM, Chernew ME, Fendrick AM (2001) Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med 135: 769–781

    PubMed  CAS  Google Scholar 

  2. Winawer SJ, Zauber AG, O’Brien MJ, Gottlieb LS, Sternberg SS; Stewart ET, Bond JH, Schapiro M, Panish JF, Waye JD et al (1992) The National Polyp Study. Design, methods and characteristics of patients with newly diagnosed polyps. The National Polyp Study Workgroup. Cancer 70 (5 Suppl): 1236–1245

    Article  PubMed  CAS  Google Scholar 

  3. Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics 1999. CA Cancer J Clin 49: 8–31

    Article  PubMed  CAS  Google Scholar 

  4. Dubois RN, Smalley WE (1996) Cyclooxygenase, NSAIDs, and colorectal cancer. J Gastroenterol 31 (6): 898–906

    CAS  Google Scholar 

  5. Burt RW (2000) Colon cancer screening. Gastroenterology 119: 837–853

    Article  PubMed  CAS  Google Scholar 

  6. Mandel JS, Church TR, Bond JH, Ederer, F, Geisser MS, Mongin SJ, Snover DC, Schuman LM (2000) The effect of fecal occult-blood screening in the incidence of colorectal cancer. N Engl J Med 343: 1603–1607

    Article  PubMed  CAS  Google Scholar 

  7. Anderson LM, May DS (1995) Has the use of cervical, breast and colorectal cancer screening increased in the United States? Am J Public Health 85: 840–842

    Article  PubMed  CAS  Google Scholar 

  8. Brown ML, Potosky AL, Thompson GB, Kessler LG (1990) The knowledge and use of screening tests for colorectal and prostate cancer: data from the 1987 National Health Interview Survey. Prey Med 19: 562–574

    Article  CAS  Google Scholar 

  9. Screening for colorectal cancer – United States (1997) MMWR Morb Mortal Wkly Rep (1999) 48: 116–121

    Google Scholar 

  10. Levin TR (2002) Flexible sigmoidoscopy for colorectal cancer screening: valid approach or short-sighted? Gastroenterol Clin North Am 31: 1015–1029

    Article  PubMed  Google Scholar 

  11. Sandler RS, Galanko JC, Murray SC, Helm JF, Woosley JT (1998) Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenoma. Gastroenterology 114: 441–447

    Article  PubMed  CAS  Google Scholar 

  12. Suh O, Mettlin C, Petrelli NJ (1993) Aspirin use, cancer, and polyps of the large bowel. Cancer 72: 1171–1177

    Article  PubMed  CAS  Google Scholar 

  13. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83: 355–358

    Article  PubMed  CAS  Google Scholar 

  14. Muscat JE, Stellman SD, Wynder EL (1994) Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 74: 1847–1854

    Article  PubMed  CAS  Google Scholar 

  15. Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y et al (2000) The effect of celecoxib, a cyclooxygenase-2-inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946–1952

    Article  PubMed  CAS  Google Scholar 

  16. DuBois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE (1998) Cyclooxygenase in biology and disease. FASEB J 12: 1063–1073

    PubMed  CAS  Google Scholar 

  17. Abramson SR, Weissman G (1989) The mechanism of action of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 32: 1–9

    Article  PubMed  CAS  Google Scholar 

  18. Smith WL, Garavito RM, DeWitt DL (1996) Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271: 33157–33160

    Article  PubMed  CAS  Google Scholar 

  19. Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular, and molecular biology. Ann Rev Biochem 69: 145–182

    Article  PubMed  CAS  Google Scholar 

  20. Isakson P, Seibert K, Masferrer J, Salvemini D, Lee L, Needleman P (1995) Discovery of a better aspirin. Adv Prostaglandin Thromboxane Leukotr Res 23: 49–54

    CAS  Google Scholar 

  21. Simon LS, Weaver AL, Graham DY, Kivith AJ, Lipsky PE, Hubbard RC, Isakson PC, Verburg KM, Yu SS, Zhao WW, Geis GS (1999) Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomised controlled trial. JAMA 282 (20): 1921–1928

    Article  PubMed  CAS  Google Scholar 

  22. DuBois RN, Awad J, Morrow J, Roberts II LJ, Bishop PR (1994) Regulation of eicasonoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. J Clin Invest 93: 493–498

    Article  PubMed  CAS  Google Scholar 

  23. Gabriel SE; Jaakkimainen L, Bombardier C (1991) Risk of serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta analysis. Ann Intern Med 115: 787–796

    PubMed  CAS  Google Scholar 

  24. MacDonald TM, Morant SV, Robinson CC, Shield MJ, McGilchrist MM, Murray FE, McDevitt DG (1997) Association of upper gastrointestinal toxicity on non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 315: 1333–1337

    Article  PubMed  CAS  Google Scholar 

  25. Henry D, Dobson A, Turner C (1993) Variability in the risk of major gastrointestinal from non-aspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 105: 1078–1088

    PubMed  CAS  Google Scholar 

  26. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA (1991) Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 114: 257–263

    PubMed  CAS  Google Scholar 

  27. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P (1990) The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265: 12013–12017

    Google Scholar 

  28. Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangmwala SH, Isakson PC, Seibert K (1995) Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. Biochem J 305: 479–484

    PubMed  CAS  Google Scholar 

  29. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM et al (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 445-(4- methylpheny1)-3- (trifluoromethyl)-1H-pyrazol-1-yllbenzenesulfonamide (SC-58635, celecoxib). J Med Chem 40: 1347–1365

    Article  PubMed  CAS  Google Scholar 

  30. Peipins LA, Sandler RS (1994) Epidemiology of colorectal adenomas. Epidemiol Rev 16: 273–297

    PubMed  CAS  Google Scholar 

  31. Neugut AI, Jacobson JS, DeVivo I (1993) Epidemiology of colorectal adenomatous polyps. Cancer Epidemiol Biomarkers Prey 2: 159–176

    CAS  Google Scholar 

  32. Gupta RA, DuBois RN, Wallace MC (2002) New avenues for the prevention of colorectal cancer: targeting cyclooxygenase-2 activity. Best Pract Res Clin Gastroenterol 16: 945–956

    Article  PubMed  CAS  Google Scholar 

  33. Fearnhead NS, Wilding JL, Bodmer WF (2002) Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. Br Med Bull 64: 27–43

    Article  PubMed  CAS  Google Scholar 

  34. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D et al (1991) Identification of FAP locus genes from chromosome 5q21. Science 253: 661–665

    Article  PubMed  CAS  Google Scholar 

  35. Bisgaard ML, Fenger K, Bulow S, Niebuhr E, Mohr J (1994) Familial adenomatous polyposis (FAP): frequency, penetrance and mutation rate. Hum Mutat 3: 121–125

    Article  PubMed  CAS  Google Scholar 

  36. Debinski HS, Love S, Spigelmann AD, Phillips K (1996) Colorectal polyp counts and cancer risk in familial adenomatous polyposis. Gastroenterology 110: 1028–1030

    Article  PubMed  CAS  Google Scholar 

  37. Waddell WR, Gasner GF, Cerise EJ, Loughry RW (1989) Sulindac for polyposis of the colon. Am J Surg 157: 175–178

    Article  PubMed  CAS  Google Scholar 

  38. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313–1316

    Article  PubMed  CAS  Google Scholar 

  39. Rigas B, Goldman IS, Levine L (1993) Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122: 518–523

    PubMed  CAS  Google Scholar 

  40. Qiao L, Kozoni V, Tsioulias GJ, Koutsos MI, Hanif R, Shiff SJ, Rigas B (1995) Selected eicosanoids increase the proliferation rat of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochem Biophys Acta 1258: 215–223

    Article  PubMed  Google Scholar 

  41. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai A, Asai S, Kimura S, Kato H, Kondo M, Hla T (1995) Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55: 3785–3789

    PubMed  CAS  Google Scholar 

  42. Shiff SJ, Koutsos MI, Qiao L, Rigas B (1996) Nonsteroidal anti-inflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 222(1): 179–188

    Article  PubMed  CAS  Google Scholar 

  43. Yao M, Kargmann S, Lam EC, Kelly CR, Zheng Y, Luk P, Kwong E, Evans JF, Wolfe MM (2003) Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 63: 586–592

    PubMed  CAS  Google Scholar 

  44. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM (1996) Suppression of intestinal polyposis in APC D716 mice by inhibition of cyclooxygenase (PGHS-2). Cell 87: 803–809

    Article  PubMed  CAS  Google Scholar 

  45. Sheng H, Shao J, Kirkland SC, Isakson g Coffey RJ, Morrow J, Beauchamp RD, Dubois RN (1997) Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99: 2254–2259

    Article  PubMed  CAS  Google Scholar 

  46. Reddy BS, Rao CV, Seibert K (1996) Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 56: 4566–4569

    PubMed  CAS  Google Scholar 

  47. Pollard M, Luckert PH (1981) Effect of indomethacine on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science 214: 558–59

    Article  PubMed  CAS  Google Scholar 

  48. Moorghen M, Ince P, Finney KJ, Sunter JP, Watson AJ, Appleton DR (1990) The effect on of sulindac on colonic tumour formation in dimethylhydrazine-treated mice. Acta Histochem 39 (Suppl): 195–199

    CAS  Google Scholar 

  49. Skinner SA, Penney AG, O’Brien PE (1991) Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch Surg 126: 1094–1096

    Article  PubMed  CAS  Google Scholar 

  50. Reddy BS, Rao CV, Rivenson A, Kelloff G (1993) Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14: 1493–1497

    Article  PubMed  CAS  Google Scholar 

  51. Ross DS, Bitzer D, Roy T, Murphy JE (1988) Piroxicam inhibits the growth of an adenocarcinoma isograft in Fisher rats. J Surg Res 45: 249–253

    Article  PubMed  CAS  Google Scholar 

  52. Pollard M, Luckert P (1984) Effect of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosourea. Cancer Lett 25: 117–121

    Article  PubMed  CAS  Google Scholar 

  53. Santini G, Sciulli MG, Marinacci R, Fusco O, Spoletini L, Pace A, Ricciardulli A, Natoli C, Procopio A, Maclouf J, Patrignani P (1999) Cyclooxygenase-independent induction of p21 WAF-1/cipl, apoptosis and differentiation by L-745,337, a selective PGH synthase-2 inhibitor, and salicylate in HT-29 cells. Apoptosis 4: 151–162

    Article  PubMed  CAS  Google Scholar 

  54. Williams C, Shattuck-Brandt RL, DuBois RN (1999) The role of COX-2 inhibitors in intestinal cancer. Ann NY Acad Sci 889: 72–83

    Article  PubMed  CAS  Google Scholar 

  55. Williams CS, Luongo D, Radhika A, Zhang T, Lamps LW, Nanney LB, Beauchamp RD, DuBois RN (1996) Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroentrology 111: 1134–1140

    Article  CAS  Google Scholar 

  56. DuBois RN, Radhika A, Reddy BS, Entingh AJ (1996) Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 111: 1134–1140

    Article  PubMed  Google Scholar 

  57. Eberhard CE, Coffey RJ, Radhika A, Giardello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183–1188

    Google Scholar 

  58. Kargman S, O’Neil G, Vickers P, Evans J, Mancini J, Jothy S (1995) Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55: 2556–2559

    PubMed  CAS  Google Scholar 

  59. Beazar-Barclay Y, Levy DB, Moser AR, Dove WF, Hamilton SR, Vogelstein B, Kinzler KW(1996) Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 17: 1757–1760

    Article  Google Scholar 

  60. Stack E, Dubois RN (2001) Role of cyclooxygenase inhibitors for the prevention of colorectal cancer. Gastroenterol Clin North Am 30(4): 1001–1010

    Article  PubMed  CAS  Google Scholar 

  61. Suleiman S, Rex DK, Sonnenberg A. (2002) Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastroenterology 122: 78–84

    Article  PubMed  Google Scholar 

  62. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas M, Karp DD; Loprinzi CL et al (2003) A randomized trial of Aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348: 883–890

    Article  PubMed  CAS  Google Scholar 

  63. Derry S, Loke YK (2000) Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 321: 1183–1187

    Article  PubMed  CAS  Google Scholar 

  64. Hawkey CJ (2000) Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 119: 521–535

    Article  PubMed  CAS  Google Scholar 

  65. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891–899

    Article  PubMed  CAS  Google Scholar 

  66. Sample D, Wargovich M, Fischer SM, Inamdar N, Schwartz P, Wang X, Do KA, Sinicrope FA (2002) A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol Biomarkers Prey 11: 275–279

    CAS  Google Scholar 

  67. Ruffin MTIV, Krishnan K, Rock CL, Normolle D, Vaerten MA, Peters-Golden M, Crowell J, Kelloff G, Boland CR, Brenner DE (1997) Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst 89: 1152–1160

    Article  PubMed  CAS  Google Scholar 

  68. Smalley W, Ray WA, Daugherty J, Griffin MR (1999) Use of nonsteroidal anti-inflammatory drugs and the incidence of colorectal cancer: a population-based study. Arch Intern Med 159: 161–166

    Article  PubMed  CAS  Google Scholar 

  69. Rosenberg L, Louik C, Shapiro S (1998) Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 82: 2326–2333

    Article  PubMed  CAS  Google Scholar 

  70. Provenzale D (2002) The cost-effectiveness of aspirin for chemoprevention of colorectal cancer. Gastroenterology 122: 230–233

    Article  PubMed  Google Scholar 

  71. Kune GA, Kune S, Watson LF (1988) Colorectal cancer risk, chronic illness, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48: 4399–4404

    PubMed  CAS  Google Scholar 

  72. Rosenberg L, Palmer JR, Zauber AG et al (1991) A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83: 355–358

    Article  PubMed  CAS  Google Scholar 

  73. Logan RF, Little J, Hawtin PG, Hardcastle JD (1993) Effect of aspirin and nonsteroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal blood screening programme. BMJ 307: 285–289

    Article  PubMed  CAS  Google Scholar 

  74. Peleg II, Maibach HT, Brown SH, Wilcox CM (1994) Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 154: 394–399

    Article  PubMed  CAS  Google Scholar 

  75. Rigau J, Pique JM, Rubio E, Olanas R, Tarrech JM, Bordas JM (1991) Effects of longterm sulindac therapy on colonic polyposis. Ann Intern Med 115: 952–954

    PubMed  CAS  Google Scholar 

  76. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Trousset M, Attali P (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101: 635–639

    PubMed  CAS  Google Scholar 

  77. Ladenheim J, Garcia G, Titzer D, Herzenberg H, Lavori P, Edson R, Omary MB (1995) Effect of sulindac on sporadic colonic polyps. Gastroenterology 108: 1083–1087

    Article  PubMed  CAS  Google Scholar 

  78. Nugent KP, Farmer KC, Spigelmann AD, Williams CB, Phillips RK (1993) Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 80: 1618–1619

    Article  PubMed  CAS  Google Scholar 

  79. North GL (2001) Celecoxib as adjunctive therapy for treatment of colorectal cancer. Ann Pharmacother 35 (12): 1638–1643

    Article  PubMed  CAS  Google Scholar 

  80. Mann M, Sheng H, Shao J, William CS, Pisacane PI, Slixkokowski MX, Dubois RN (2001) Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120: 1713–1719

    Article  PubMed  CAS  Google Scholar 

  81. Ricchi P, Zarilli R, di Palma A, Acquaviva AM (2003) Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer 88: 803–807

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hospital of Liestal, Rheinstrasse 26, Liestal, CH-4410, Switzerland

    Christoph A. Maurer & Katharina M. Kessler

Authors
  1. Christoph A. Maurer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katharina M. Kessler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. TAP Pharmaceuticals, 675 North Field Dr., Lake Forest, IL, 60045, USA

    Douglas W. Morgan

  2. IPF PharmaCeuticals, Feodor-Lynen-Strasse 31, Hannover, 30625, Germany

    Ulf J. Forssmann

  3. Oncology Research, Centocor, 200 Great Valley Parkway, Malvern, PA, 19355, USA

    Marian T. Nakada

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Basel AG

About this chapter

Cite this chapter

Maurer, C.A., Kessler, K.M. (2004). Effects of cyclooxygenase-2 (COX-2) inhibitors in colorectal cancer. In: Morgan, D.W., Forssmann, U.J., Nakada, M.T. (eds) Cancer and Inflammation. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-7861-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-7861-6_8

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9600-9

  • Online ISBN: 978-3-0348-7861-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation